Neuroactive steroids and their role in epilepsy


  • Chetan Y. Patil Department of Pharmacology, Government Medical College and Hospital, Aurangabad- 431001, Maharashtra, India
  • Shamsundar A. Jadhav Department of Pharmacology, Government Medical College and Hospital, Aurangabad- 431001, Maharashtra, India
  • Sudhakar M. Doifode Department of Pharmacology, Government Medical College and Hospital, Aurangabad- 431001, Maharashtra, India
  • Mirza Shiraz Baig Department of Pharmacology, Government Medical College and Hospital, Aurangabad- 431001, Maharashtra, India


Neuroactive steroids, Neurosteroids, Allopregnanolone, Tetrahydrodeoxycorticosterone (THDOC), GABAA receptor, Catamenial epilepsy, Seizure, Epilepsy


Neuroactive steroids are the certain steroids that alter neuronal excitability via the cell surface through interaction with certain neurotransmitter receptors. Neuroactive steroids regulate physiological functions of the central nervous system and have possible therapeutic potential in neurological diseases. They have been shown to affect neuronal excitability via their interaction with the ligand-gated ion channel family, such as the GABAA receptor by acting genomically as well as nongenomically. Positive modulators of GABAA receptor have anticonvulsant action as they enhance GABAergic transmission thereby increasing the seizure threshold. By virtue of these properties, neurosteroids appear to be relevant to pathophysiology and pharmacological treatment of many neurological diseases including catamenial epilepsy, stress induced epilepsy, temporal lobe epilepsy, alcohol withdrawal seizures, infantile spasm and status epilepticus. So far, only synthetic neurosteroid, ganaxolone has been tried in treatment of epilepsy and has shown good efficacy and tolerability. But, human data of trials are limited and hence, large double-blinded, placebo-controlled, randomized clinical trials are required before their use. The paper reviews the biosynthesis and GABAA receptor modulation of neurosteroids and their potential role in epilepsy.


Rupprecht R. Neuroactive steroids: Mechanisms of action and neuropsychopharmacological properties. Psychoneuroendocrinology 2003;28:139-68.

Zheng P. Neuroactive steroid regulation of neurotransmitter release in the CNS: Action, mechanism and possible significance. Prog Neurobiol 2009;89:134-52.

Melcangi RC, Panzica G, Garcia-Segura LM. Neuroactive steroids: Focus on human brain. Neuroscience 2011;191:1-5.

Reddy DS. Role of anticonvulsant and antiepileptogenic neurosteroids in the pathophysiology and treatment of epilepsy. Front Endocrinol (Lausanne) 2011;2:38.

Morrow AL. Recent developments in the significance and therapeutic relevance of neuroactive steroids--Introduction to the special issue. Pharmacol Ther 2007;116:1-6.

Rupprecht R, di Michele F, Hermann B, Ströhle A, Lancel M, Romeo E, et al. Neuroactive steroids: Molecular mechanisms of action and implications for neuropsychopharmacology. Brain Res Brain Res Rev 2001;37:59-67.

Akk G, Covey DF, Evers AS, Steinbach JH, Zorumski CF, Mennerick S. Mechanisms of neurosteroid interactions with GABA(A) receptors. Pharmacol Ther 2007;116:35-57.

Mellon SH, Griffin LD. Neurosteroids: Biochemistry and clinical significance. Trends Endocrinol Metab 2002;13:35-43.

Herd MB, Belelli D, Lambert JJ. Neurosteroid modulation of synaptic and extrasynaptic GABA(A) receptors. Pharmacol Ther 2007;116:20-34.

Kokate TG, Svensson BE, Rogawski MA. Anticonvulsant activity of neuroactive steroids: correlation with gamma-aminobutyric acid-evoked chloride current potentiation. J Pharmacol Exp Ther 1994;270:1223-9.

Belelli D, Bolger MB, Gee KW. Anticonvulsant profile of the progesterone metabolite 5α-pregnan-3α-ol-20-one. Eur J Pharmacol 1989;166:325-9.

Frye CA. The neuroactive steroid 3α,5α-THP has anti-seizure and possible neuroprotective effects in an animal model of epilepsy. Brain Res 1995;696:113-20.

Wieland S, Belluzzi JD, Stein L, Lan NC. Comparative behavioral characterization of the neuroactive steroids 3α-OH,5α-pregnan-20-one and 3α-OH,5β-pregnan-20-one in rodents. Psychopharmacology 1995;118:65-71.

Citraro R, Russo E, Di Paola ED, Ibbadu GF, Gratteri S, Marra R, De Sarro G. Effects of some neurosteroids injected into some brain areas of WAG/Rij rats, an animal model of generalized absence epilepsy. Neuropharmacology 2006;50:1059-71.

Snead OC 3rd. Ganaxolone, a selective, high-affinity steroid modulator of the γ-aminobutyric acid-A receptor, exacerbates seizures in animal models of absence. Ann Neurol 1998;44:688-91.

Reddy DS, Rogawski MA. Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself. J Pharmacol Exp Ther 2000;295:1241-8.

Kokate TG, Yamaguchi S, Pannell LK, Rajamani U, Carroll DM, Grossman AB, Rogawski MA. Lack of anticonvulsant tolerance to the neuroactive steroid pregnanolone in mice. J Pharmacol Exp Ther 1998;287:553-8.

Williamson J, Mtchedlishvili Z, Kapur J. Characterization of the convulsant action of pregnenolone sulfate. Neuropharmacology 2004;46:856-64.

Reddy DS, Kulkarni SK. Proconvulsant effects of neurosteroid pregnenolone sulfate and dehydroepiandrosterone sulfate in mice. Eur J Pharmacol 1998;345:55-9.

Biagini G, Panuccio G, Avoli M. Neurosteroids and epilepsy. Curr Opin Neurol 2010;23:170-6.

Biagini G, Longo D, Baldelli E, Zoli M, Rogawski MA, Bertazzoni G, Avoli M. Neurosteroids and epileptogenesis in the pilocarpine model: Evidence for a relationship between P450scc induction and length of the latent period. Epilepsia 2009;50 Suppl 1:53-8.

Biagini G, Baldelli E, Longo D, Pradelli L, Zini I, Rogawski MA, Avoli M. Endogenous neurosteroids modulate epileptogenesis in a model of temporal lobe epilepsy. Exp Neurol 2006;201:519-24.

Monaghan EP, McAuley JW, Data JL. Ganaxolone: a novel positive allosteric modulator of the GABAA receptor complex for the treatment of epilepsy. Expert Opin Investig Drugs 1999;8:1663-71.

Reddy DS, Rogawski MA. Neurosteroid replacement therapy for catamenial epilepsy. Neurotherapeutics 2009;6:392-401.

Reddy DS. The role of neurosteroids in the pathophysiology and treatment of catamenial epilepsy. Epilepsy Res 2009;85:1-30.

Bazan AC, Montenegro MA, Cendes F, Min LL, Guerreiro CA. Menstrual cycle worsening of epileptic seizures in women with symptomatic focal epilepsy. Arg Neuropsiguiatr 2005;63(3B):751-6.

Herzog AG, Harden CL, Liporace J, Pennell P, Schomer DL, Sperling M, Fowler K, Nikolov B, Shuman S, Newman M. Frequency of catamenial seizure exacerbation in women with localization-related epilepsy. Ann Neurol 2004;56:431-4.

Tuveri A, Paoletti AM, Orrù M, Melis GB, Marotto MF, Zedda P, Marrosu F, Sogliano C, Marra C, Biggio G, Concas A. Reduced serum level of THDOC, an anticonvulsant steroid, in women with perimenstrual catamenial epilepsy. Epilepsia 2008;49:1221-9.

Gangisetty O, Reddy DS. Neurosteroid withdrawal regulates GABAA receptor alpha4-subunit expression and seizure susceptibility by activation of progesterone receptor-independent early growth response factor-3 pathway. Neuroscience 2010;170:865-80.

Shen H, Gong QH, Yuan M, Smith SS. Short-term steroid treatment increases δ GABAA receptor subunit expression in rat CA1 hippocampus: pharmacological and behavioral effects. Neuropharmacology 2005;49:573-86.

Maguire JL, Stell BM, Rafizadeh M, Mody I. Ovarian cycle-linked changes in GABAA receptors mediating tonic inhibition alter seizure susceptibility and anxiety. Nat Neurosci 2005;8:797-804.

Smith SS, Gong QH. Neurosteroid administration and withdrawal alter GABAA receptor kinetics in CA1 hippocampus of female rats. J Physiol 2005;564:421-36.

Reddy DS, Rogawski MA. Enhanced anticonvulsant activity of neuroactive steroids in a rat model of catamenial epilepsy. Epilepsia 2001;42:303-10.

Reddy DS, Rogawski MA. Enhanced anticonvulsant activity of ganaxolone after neurosteroid withdrawal in a rat model of catamenial epilepsy. J Pharmacol Exp Ther 2000;294:909-15.

Lawrence C, Martin BS, Sun C, Williamson J, Kapur J. Endogenous neurosteroid synthesis modulates seizure frequency. Ann Neurol 2010;67:689-93.

McAuley JW, Moore JL, Reeves AL, Flyak J, Monaghan EP, Data J. A pilot study of the neurosteroid ganaxolone in catamenial epilepsy: clinical experience in two patients. Epilepsia 2001;42:85.

Herzog AG, Fowler KM, Smithson SD, Kalayjian LA, Heck CN, Sperling MR, Liporace JD, Harden CL, Dworetzky BA, Pennell PB, Massaro JM. Progesterone vs placebo therapy for women with epilepsy: A randomized clinical trial. Neurology 2012;78:1959-66.

Herzog AG. Hormonal therapies: progesterone. Neurotherapeutics 2009;6:383-91.

Biggio G, Concas A, Follesa P, Sanna E, Serra M. Stress, ethanol, and neuroactive steroids. Pharmacol Ther 2007;116:140-71.

Reddy DS. Physiological role of adrenal deoxycorticosterone-derived neuroactive steroids in stress-sensitive conditions. Neuroscience 2006;138:911-20.

Reddy DS, Rogawski MA. Stress-induced deoxycorticosterone-derived neuroactive steroids modulates GABAA receptor function and seizure susceptibility. J Neurosci 2002;42:3795-805.

Barbaccia ML, Roscetti G, Trabucchi M, Mostallino MC, Concas A, Purdy RH, Biggio G. Timedependent changes in rat brain neuroactive steroid concentrations and GABAA receptor function after acute stress. Neuroendocrinology 1996;63:166-72.

Barbaccia ML, Roscetti G, Trabucchi M, Purdy RH, Mostallino MC, Concas A, Biggio G. The effects of inhibitors of GABAergic transmission and stress on brain and plasma allopregnanolone concentrations. Br J Pharmacol 1997;120:1582-8.

Parízek A, Hill M, Kancheva R, Havlíková H, Kancheva L, Cindr J, Pasková A, Pouzar V, Cerny I, Drbohlav P, Hájek Z, Stárka L. Neuroactive pregnanolone isomers during pregnancy. J Clin Endocrinol Metab 2005;90:395-403.

Frucht MM, Quigg M, Schwaner C, Fountain NB. Distribution of seizure precipitants among epilepsy syndromes. Epilepsia 2000;41:1534-9.

Edwards HE, MacLusky NJ, Burnham WM. Epileptic seizures: Do they cause reproductive dysfunction? Univ Toronto Med J 2000;77:104-11.

Herzog AG. Altered reproductive endocrine regulation in men with epilepsy: implications for reproductive function and seizures. Ann Neurol 2002;51:539-42.

Bauer J, Stoffel-Wagner B, Flügel D, Kluge M, Schramm J, Bidlingmaier F, Elger CE. Serum androgens return to normal after temporal lobe epilepsy surgery in men. Neurology 2000;55:820-24.

Reddy DS. Anticonvulsant activity of the testosterone-derived neurosteroid 3α-androstanediol. Neuroreport 2004;15:515-8.

Reddy DS. Testosterone modulation of seizure susceptibility is mediated by neurosteroids 3α- androstanediol and 17β-estradiol. Neuroscience 2004;129:195-207.

Zhang N, Wei W, Mody I, Houser CR. Altered localization of GABAA receptor subunits on dentate granule cell dendrites influences tonic and phasic inhibition in a mouse model of epilepsy. J Neurosci 2007;27:7520-31.

Sun C, Mtchedlishvili Z, Erisir A, Kapur J. Diminished neurosteroid sensitivity of synaptic inhibition and altered location of the α4 subunit of GABAA receptors in an animal model of epilepsy. J Neurosci 2007;27:12641-50.

Morrow AL, Porcu P, Boyd KN, Grant KA. Hypothalamic-pituitary-adrenal axis modulation of GABAergic neuroactive steroids influences ethanol sensitivity and drinking behavior. Dialogues Clin Neurosci 2006;8:463-77.

N’Gouemo P, Rogawski MA. Alcohol withdrawal seizures. In: Pitkänen A, Schwartzkroin PA, Moshé SL, editors. Models of Seizures and Epilepsy. Amsterdam: Elsevier Academic Press; 2006:161-77.

Kuruba R, Reddy DS. Neuroprotective effects of GABAergic agents in the rat model of refractory status epilepticus. Soc Neurosci Abstr 2011;PN 338.08.

Shields WD. Infantile Spasms: Little Seizures, BIG Consequences. Epilepsy Curr 2006;6:63-9.

Anovadiya AP, Sanmukhani JJ, Tripathi CB. Epilepsy: Novel therapeutic targets. J Pharmacol Pharmacother 2012;3:112-7.




How to Cite

Patil, C. Y., Jadhav, S. A., Doifode, S. M., & Baig, M. S. (2017). Neuroactive steroids and their role in epilepsy. International Journal of Basic & Clinical Pharmacology, 1(3), 150–159. Retrieved from



Review Articles